METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Clinical trials for METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Immune-Targeting drug shows promise against tough stomach cancers
Disease control OngoingThis study tested whether adding the drug zolbetuximab to standard chemotherapy works better than chemotherapy alone for adults with advanced stomach or gastroesophageal (GEJ) cancer that has spread and cannot be removed by surgery. Zolbetuximab is designed to attach to a specifi…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New Immune-Targeting drug tested in global fight against advanced stomach cancer
Disease control OngoingThis study is testing whether adding the drug zolbetuximab to standard chemotherapy works better than chemotherapy alone for adults with advanced stomach or GEJ (where the food pipe meets the stomach) cancer that has spread and cannot be removed by surgery. The drug is designed t…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC